Key Points
SummaryCompaniesWegovy is from GLP-1 class of highly effective weight loss drugs44% of people taking Wegovy experience nauseaBiotech firms aim for effective weight-loss drugs without nauseaInvestors take note of demand for more treatmentsObesity market could be worth $100 bln by 2030-analysts..
LONDON, July 7 (Reuters) - Weight-loss drug Wegovy helped Rebecca Vogt achieve a major goal - shedding the weight she had not managed to drop since giving birth..
More than a dozen small, privately-owned companies are developing drugs that hold the promise of Wegovy-like weight loss without the downside of nausea, according to U.S. investment bank Stifel (SF.N), which published reports in March and July on the obesity market...
Novo, Lilly and other big drugmakers including Pfizer (PFE.N) have said they are working on a second generation of weight-loss drugs that improve on Wegovy and Mounjaro by offering pills instead of injections or by potentially leading to greater weight loss...
Rivus said its main drug in development, HU6, showed in an early, eight-week "proof of concept" study to cause weight loss comparable to the GLP-1 drugs while sparing muscle mass and avoiding nausea..
You might be interested in
Roche enters obesity drugs race with $2.7 bln Carmot deal
04, Dec, 23The race to grab a slice of the lucrative market for obesity treatments is heating up among drugmakers, with Swiss company Roche (ROG.S) becoming one of the latest entrants following its $2.7 billion deal to buy Carmot Therapeutics (CRMO.O).
Weight loss drugs transforming healthcare, may help with addiction
09, Nov, 23A new class of weight loss drugs is transforming the U.S. healthcare system in ways that could extend to equally hard-to-treat areas like substance abuse, according to speakers at the Reuters Events Total Health conference in Chicago this week.
Adherence to weight-loss drugs is far higher with Wegovy than older medicines
06, Dec, 23Forty percent of patients who filled a prescription for Novo Nordisk's (NOVOb.CO) Wegovy to treat obesity in 2021 or 2022 were still taking it a year later, more than three times the rate of adherence with older medicines, according to an analysis of medical records and insurance claims data.
Stars who have taken weight loss drugs like Ozempic, Wegovy
16, Mar, 23Jimmy Kimmel said: "When I look around this room, I can't help but wonder 'Is Ozempic right for me?'" while presenting the 2023 Oscars.
Why People Stop Using Drugs Like Ozempic
07, Jul, 23Drugs like semaglutide—better known as Ozempic or Wegovy—could be lifelong treatments for obesity, but what little data scientists have suggests that people don't stick with them for long.
The Obesity Drug Revolution Just Got Real
08, Aug, 23Wegovy reduces risk of heart attack, stroke in study, paving way for greater insurance coverage
Novo, Lilly rivals explore booming weight-loss drug market entry
08, Dec, 23Novo Nordisk (NOVOb.CO) and Eli Lilly (LLY.N) have pulled ahead in the race for a slice of the weight-loss drugs market, expected to be worth $100 billion by the end of the decade, and rivals are looking to catch up through acquisitions and trials.
Has a 'magical' weight loss drug finally arrived? Hopes soar with US firm's never-before-seen results
29, Jun, 23Patients who got a weekly injection of the experimental anti-obesity drug retatrutide lost up to 24 per cent of their body weight in 48 weeks, show phase-2 trials published this week.
New report: Most patients stop taking Wegovy after one year
12, Jul, 23A report published by Reuters shows a substantial drop in the number of people who stick to taking weight-loss medications like Wegovy one year out.
Novo Nordisk rivals see room to compete in $100 billion weight-loss drug market
05, May, 23The enormous demand for weight-loss treatments like Novo Nordisk’s Wegovy could support as many as 10 competing products with annual sales reaching up to $100 billion within a decade, mostly in the United States, industry executives and analysts said.